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Osteoarticular infections in paediatric sickle cell disease: in the
era of multidrugresistant bacteria
Osteomyelitis (OM) is a major cause of morbidity in sickle
cell disease (SCD) patients (Thanni, 2006; Tarer et al., 2006)
with Staphylococcus aureus and the Salmonella species being
the most frequently isolated microorganisms (Burnett et al.,
1998; Thanni, 2006). In recent years, we have observed an
increasing number of patients in our institution with severe
multifocal, multidrug‐resistant (MDR) osteoarticular infec-
tions (OAI). We are trying to determine OAI incidence, aeti-
ology and management in children with SCD and evaluate
MDR strain emergence.
We performed a longitudinal, prospective, observational
data analysis of SCD children with OAI (<18 years old)
admitted to a tertiary care paediatric hospital in Lisbon, Por-
tugal from January 2010 to December 2018. Clinical and
microbiological data, imaging, treatment and evolution were
obtained. OM and septic arthritis (SA), complications and
sequelae (Arnold & Bradley, 2001), and MDR were defined
according to previous published criteria (Magiorakos et al.,
2012). Quantitative and categorical variables were compared
using non‐parametric tests. SPSS Statistics version 24 was
used.
Fifteen of the 165 (9·1%) patients with SCD had OAI, all SS
homozygous, with a fetal hemoglobin level of 8·4 ± 6·6 (sim-
ilar to other SCD patients), a median age of eight years
[IQR2–11], 53·3% female, and all of African origin: nine lived
in Portugal and six lived in Portuguese speaking african coun-
tries (PALOP) and travelled to Portugal for medical care.
The most frequent clinical and imaging findings are pre-
sented in Table I. The majority (40%) were admitted with
the diagnosis of vaso‐occlusive crisis. All were diagnosed with
OM and 10 had concomitant SA. Five already had chronic
OM on admission, and six had multifocal involvement
(range 2–11). A pathogen was identified in seven patients
(41%) (with one patient with SAMS plus Pseudomonas), by
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positive cultures (N = 8) or molecular amplification (N = 2):
blood culture in two (2/15; 13%), culture from synovial fluid
in four (4/6; 67%) and bone sample in two (2/8; 25%). The
most common identified bacteria were MDR Serratia marces-
cens (N = 3), methicillin‐susceptible S. aureus (N = 2), MDR
Enterobacter cloacae (N = 1), MDR Pseudomonas aeruginosa
(N = 1) and Enterococcus faecium (N = 1; molecular amplifi-
cation). Most patients were empirically treated with a third
generation cephalosporin (N = 8) or flucloxacillin (N = 4)
plus gentamicin. After bacterial identification, treatment was
modified to meropenem (N = 5) plus amikacin (N = 3) or
flucloxacillin (N = 1). The median duration of intravenous
and total antibiotic treatment was 21 days (IQR 16–69) and
six weeks (IQR 5–10 weeks), respectively. Ten patients were
discharged on oral antibiotics: cefuroxime (N = 5), levofloxa-
cin plus rifampicin (N = 3) or flucloxacillin (N = 2).
Eight (53%) patients underwent surgical procedures, seven
more than one intervention (range 2–11), including arthro-
centesis, arthrotomy, bone drainage and debridement, and
26·6% received hyperbaric oxygen therapy.
Comparing data from children with MDR bacteria
(N = 6) to that of children with no isolation or susceptible
bacteria (N = 9) (Table II), the median number of complica-
tions was three [IQR 2·5–5] versus 0 [IQR 0–0.5]. Complica-
tions in the MDR group included pathologic fractures
(N = 2), intraosseous or subperiosteal abscesses (N = 6),
avascular necrosis (N = 4) and progression to chronic
osteomyelitis (N = 5). In the non‐MDR group, complications
were intraosseous abscesses (N = 2) and chronic osteomyeli-
tis (N = 1). At 12 months follow‐up, only the MDR sub-
group presented sequelae: functional limitation (N = 5),
dysmetria (N = 2), stiffness (N = 1) and angular deformity
Table I. Clinical and imagiologic data for 15 patients.
Variable Value
Gap between symptoms and admission, days
(median, IQR)
7 [5–22]
Gap between admission and diagnosis, median
(median, IQR)
5 [2‐12]
Pain (N, %) 15 (100)
Functional limitation (N, %) 13 (86.7)
Fever >38·2ºC (N, %) 11 (73.3)
Local inflammatory signs (N, %) 11 (73.4)
Leukocyte count >15·000/ml (N, %) 12 (80)
C‐reactive protein >20 mg/ (N, %) 13 (86.6)
Sedimentation rate >20 mm/h (N, %) 15 (100)










Abnormal at admission (N, %) 11 (73·3)
Evident avascular necrosis (N, %) 6 (40)
Lytic changes (N, %) 7 (46·7)
Periosteal reaction(N, %) 8 (53·3)
Ultrasonography
Abscesses (N, %) 6 (40)
MRI
Abnormal (N, %) 15 (100)
Long bones osteonecrosis (N, %) 14 (93·3)
Signal intensity alterations and gadolinium (N, %) 15 (100)
Soft tissue abscesses (N, %) 10 (66·7)
Table II. Comparing children with MDR bacteria with children






N = 9 P
Age (median, IQR,
years)
10 [7–15.2] 5 [1·6–9.5] 0·04




6 (100) 0 (0) 0·000
Previous hospital
admission (N, %)
6 (100) 6 (67) 0·2
PALOP
provenance (N, %)






22[9–105] 5 [1–8] 0·119












79·5 ± 94·7 20 ± 15 0·001
Days IV antibiotic
(median, IQR)









2·5 [2–5.8] 0·0 [0–0·5] 0·001
Complications
(N, %)
6(100) 2 (22) 0·015
Sequelae at
12 months (N, %)
83 0 0·002
PALOP, Portuguese speaking african countries.
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(N = 1). Two patients in the MDR group required a dorso‐
lumbo‐sacral orthosis, three needed crutches and five needed
physical therapy. Risk factors for MDR infections were
provenance from PALOP (odds ratio [OR], 20·4], 95% con-
fidence interval [CI], 0·855–489]) and previous multiple
antibiotic courses (OR 247 [4·3–14 106]).
The OM incidence in our series (13%) was comparable to
the 12–16·3% reported by Neonato et al. in 299 homozygous
SCD patients in France (Neonato et al., 2000), most Hb SS
(Bennett & Namnyak, 1990), with a median age between
nine and 15·7 years (Epps et al., 1991; Sadat‐Ali, 1998). We
observed a higher rate of multifocal disease (41%) than usu-
ally described (10–34%) (Sadat‐Ali, 1998; Chambers et al.,
2000), but similar to that reported by Ebong (42%) in Nige-
ria (Ebong,1986). These differences can most likely be
explained by the small sample size of most series.
OM and osteonecrosis are often associated and coincident,
varying from 49% to 74%, slightly higher than our data
(40%). (Bennett & Namnyak, 1990; Hernigou et al., 2010).
Differentiating a bone infarct from OM is extremely difficult.
As previously reported, in our study the combination of
fever and local swelling, in an ill‐appearing patient, together
with a high CRP (C‐reactive protein level) and ESR (erythro-
cyte sedimentation rate) and contrast‐enhanced T1‐weighted
images was suggestive of infection (Chambers et al., 2000;
Almeida & Roberts, 2005; Hernigou et al., 2010; Kosaraju
et al., 2017). Bone culture was only collected from compli-
cated cases, justifying the low (40%) microbiologic yield in
our study.
The aetiology is changing and varies geographically
(Thanni, 2006). In most studies, Salmonella and S. aureus
predominate, with a 2·2:1 ratio (Burnett et al., 1998). How-
ever, other Gram‐negative bacilli (GNB) (18–19·6%) ranked
almost equal to S. aureus (Burnett et al., 1998; Thanni,
2006), similar to recent data from GNB bacteraemia in SCD
patients (14–26%) (Williams et al., 2009). Salmonella was
not a common cause of OM in our study, but MDR‐GNB
was frequent (62·5%). We know that MDR‐GNB colonisa-
tion is rising, suggesting that intestinal colonisation might
have led to infection in our SCD patients.
Treatment is generally continued for six weeks, but much
longer for complicated, MDR infections (Chambers et al.,
2000). However, most studies are old and it is likely that for
uncomplicated, non‐MDR infections, we could use shorter
intravenous courses.
Complications are higher than reported in healthy chil-
dren. Epps et al. (1991) reported joint stiffness in 20%,
pathological fracture in 6·6% and chronic OM in 27%,
which healed in 6–14 months. We had a higher progression
to chronic OM (40%) and functional limitation (33%): mul-
tifocal, MDR infections probably account for these differ-
ences.
Our study has limitations, being a small and heteroge-
neous sample, but all patients were cared for by the same
multidisciplinary team. OAI are still a major health problem
in SCD patients and multifocal, severe MDR‐GNB infections









1Infectious Diseases Unit, Área de Pediatria, Hospital Dona
Estefania, Centro Hospitalar Universitário de Lisboa Central EPE,
2Nova Medical School, Faculdade de Ciências Médicas,
Universidade Nova de Lisboa, 3Pediatric Orthopedic Unit,
Área de Pediatria, Hospital de Dona Estefânia,
4Centro Tecnológico e Biomédico, Radiodiagnóstico,
Polo Hospital de Dona Estefânia and 5Hematology Diseases Unit,
Área de Pediatria, Centro Hospitalar Universitário de
Lisboa Central EPE Portugal.
E-mail: cmfgouveia@gmail.com
First published online 9 March 2020
doi: 10.1111/bjh.16568
References
Almeida, A. & Roberts, I. (2005) Bone involve-
ment in sickle cell disease. British Jounal of Hae-
matology, 129, 482–490.
Arnold, J. & Bradley, J. (2001) Osteoarticular
Infections in Children. Infectious Diseases Clini-
cal North American, 29, 557–574.
Bennett, O.M. & Namnyak, S.S. (1990) Bone and
joint manifestations of sickle cell anaemia. The
Journal of Bone and Joint Surgery British Volume,
72, 494–499.
Burnett, M.W., Bass, J.W. & Cook, B.A. (1998)
Etiology of osteomyelitis complicating sickle cell
disease. Pediatrics, 101, 296–297.
Chambers, J.B., Forsythe, D.A., Bertrand, S.L.,
Iwinski, H.J. & Steflik, D.E. (2000) Retrospective
review of osteoarticular infections in a pediatric
sickle cell age group. Journal of Pediatric Ortho-
paedics, 20, 682–685.
Ebong, W.W. (1986) Acute osteomyelitis in Nigeri-
ans with sickle cell disease. Annals of the Rheu-
matic Diseases, 45, 911–915.
Epps, C.H., Bryant, D.D., Coles, M.J. & Castro, O.
(1991) Osteomyelitis in patients who have
sickle‐cell disease. Diagnosis and management.
The Journal of Bone and Joint Surgery. American
Volume, 73, 1281–1294.
Hernigou, P., Daltro, G., Flouzat‐Lachaniette,
C.H., Roussignol, X. & Poignard, A. (2010)
Septic arthritis in adults with sickle cell disease
often is associated with osteomyelitis or
osteonecrosis. Clinical Orthopaedics and Related
Research, 468, 1676–1681.
Kosaraju, V., Harwani, A., Partovi, S., Bhojwani,
N., Garg, V., Ayyappan, S., Kosmas, C. & Rob-
bin, M. (2017) Imaging of musculoskeletal man-
ifestations in sickle cell disease patients. British
Jounal of Radiology, 90, 1–9.
Magiorakos, A.P., Srinivasan, A., Carey, R.B., Car-
meli, Y., Falagas, M.E., Giske, C.G., Harbarth,
S., Hindler, J.F., Kahlmeter, G., Olsson‐Liljeq-
uist, B., Paterson, D.L., Rice, L.B., Stelling, J.,
Struelens, M.J., Vatopoulos, A., Weber, J.T. &
Monnet, D.L. (2012) Multidrug‐resistant,
Correspondence
ª 2020 British Society for Haematology and John Wiley & Sons Ltd e149
British Journal of Haematology, 2020, 189, e119–e187
extensively drug‐resistant and pandrug‐resistant
bacteria: an international expert proposal for
interim standard definitions for acquired resis-
tance. Clinical Microbiology and Infection, 18,
268–281.
Neonato, M.G., Guilloud‐Bataille, M., Beauvais, P.,
Bégué, P., Belloy, M., Benkerrou, M., Ducrocq,
R., Maier‐Redelsperger, M., de Montalembert,
M., Quinet, B., Elion, J., Feingold, J. & Girot, R.
(2000) Acute clinical events in 299 homozygous
sickle cell patients living in France. French Study
Group on Sickle Cell Disease. European Journal
of Haematolology, 65, 155–164.
Sadat‐Ali, M. (1998) The status of acute
osteomyelitis in sickle cell disease. A 15‐year
review. International Surgery, 83, 84–87.
Tarer, V., Etienne‐Julan, M., Diara, J.P., Belloy,
M., Mukizi‐Mukaza, M., Elion, J. & Romana,
M. (2006) Sickle cell anemia in Guadeloupean
children: pattern and prevalence of acute clinical
events. European Journal of Haematology, 76,
193–199.
Thanni, L. (2006) Bacterial osteomyelitis in major
sickling haemoglobinopathies: geographic differ-
ence in pathogen prevalence. African Health
Sciences, 6, 236–239.
Williams, T.N., Uyoga, S., Macharia, A., Ndila, C.,
McAuley, C.F., Opi, D.H., Mwarumba, S.,
Makani, J., Komba, A., Ndiritu, M.N., Sharif,
S.K., Marsh, K., Berkley, J.A. & Scott, J.A.
(2009) Bacteraemia in Kenyan children with
sickle‐cell anaemia: a retrospective cohort and
case–control study. The Lancet, 374, 1364–1370.
Test trial of spike-in immunoglobulin heavy-chain (IGH) con-
trols for next generation sequencing quantification of minimal
residual disease in acute lymphoblastic leukaemia
Minimal residual disease (MRD) is the strongest prognostic
factor for acute lymphoblastic leukaemia (ALL). Next genera-
tion sequencing (NGS) of immunoglobulin/T-cell receptor
(Ig/TCR) repertoires is a promising technology for MRD
assessment, overcoming many limitations of current quanti-
tative polymerase chain reaction (qPCR) methods. One chal-
lenge for using NGS for MRD consists of normalising the
number of reads related to the leukaemia clonotype into its
molecule copy number (Knecht et al., 2019). In the present
study, we validated in a clinical setting the use of
immunoglobulin heavy-chain (IGH) spike-in control plas-
mids (n = 19) for assessing MRD by NGS (Fig 1A). Reper-
toire analysis was performed by Vidjil-algo (Duez et al,
2016), and MRD calculations were done using an in-house
Python script. We achieved results that were better or com-
parable to those demonstrated by other published methods,
which either did not use spike-in controls (Kotrova et al,
2015; Shin et al, 2017), relied on trade secret methodologies
(Faham et al, 2012; Cheng et al, 2018), or did not explore
how their systems work (Ladetto et al, 2014; Sekiya et al,
2017; Theunissen et al, 2019).
In pilot tests, we observed the need of plasmid lineariza-
tion before use (Figure S1). Additionally, use of spike-ins at
high copy numbers (360–1080) consumed a large portion
(552%) of the sample’s reads (Figure S2). Therefore, subse-
quent experiments were performed using 19 IGH V(D)J
sequences, comprehending 2–3 different clones per VH seg-
ment (VH1–7), at final amounts of 10, 40 and 160 copies
per reaction. Detailed methods are available as Supplemental
Data.
This spike-in system was validated in retrospective samples
from 110 consecutive patients with B-cell precursor (BCP)-
ALL (ethical approval Certificado de Apresentac~ao para
Apreciac~ao Etica [CAAE]: 57280616.4.0000.5376) that
presented IGH complete rearrangements, as determined in
prospective Ig/TCR screening for MRD analysis by qPCR.
The numbers of VH-(DH)-JH clonotypes identified at diag-
nosis (day 0, D0) by conventional MRD screening and NGS
are shown in Table I. NGS identified two or more leukaemia
clonotypes in more patients (60%) than homo/heteroduplex
screening used in the qPCR method (364%). Of note, 20
patients presented with two or more leukaemia clonotypes
with identical (IgHD)-N-IgHJ regions, indicating clonal evo-
lution.
The average number of NGS reads/patient in day 35
(D35) follow-up samples was 663 034 (438% spike-in). The
MRDspike.py script (Data S1) was developed to calculate
MRD values. Two fitting models (examples in Fig 1B) for
spike-in normalisation were used:
1 Family fitting: calculates different predictive models for
each VH family, which is applied for each leukaemia
clonotype according to its family.
2 Universal fitting: a consensus predictive model, indepen-
dent of VH families, used over Family fitting if: (i) the
leukaemia clonotype’s VH family cannot be determined;
(ii) less than two different spike-in are identified for the
leukaemia’s VH family; (iii) R2 ≤ 08 for Family fitting.
A total of 129 IGH markers had MRD calculated by both
qPCR and NGS (Table SIII). Read frequency normalisation
into NGS MRD was performed by Family fitting in most
cases (868%). Read frequencies of spike-in molecules dif-
fered across different VH families, likely reflecting variable
primer efficiencies (Figure S4). However, MRD by Universal
and Family fitting were highly correlated (Figure S5) and
equally accurate in comparison to qPCR (Table SIV). Nota-
bly, NGS MRD accuracy did not correlate with the number
of spike-in reads (Figure S6).
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